<DOC>
	<DOCNO>NCT02788565</DOCNO>
	<brief_summary>Data study contribute additional knowledge regard patient outcome direct somatostatin analogue ( SSA ) treatment related cost clinical practice Nordic country . Such knowledge importance treatment decision , decision support development care , follow training patient primary care nurse .</brief_summary>
	<brief_title>Quality Life , Treatment Experience Cost Treatment With Somatostatin Analogues Patients With Gastroenteropancreatic Neuroendocrine Tumours</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>Signed informed consent Diagnosed Gastroenteropancreatic Neuroendocrine Tumour ( GEPNET ) treat SSA least three month 3 year GEPNET proliferation index Ki 67 &lt; 10 % Over 18 year age No specific exclusion criterion define</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>